COMMUNIQUÉS West-GlobeNewswire

Felix Health to Lower Semaglutide Pricing by Up to 65% as Lower-Cost Options Enter Canada
12/05/2026
Canada’s largest virtual weight loss clinic says cost is causing patients to discontinue treatment: Nearly 1 in 4 Felix weight management patients who discontinued their program in the past year cited cost as the #1 [...]
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/05/2026
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a [...]
Vireo Growth Inc. Announces First Quarter 2026 Results
12/05/2026
Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4 th largest cannabis company on a pro forma basis by revenue Closed the Schwazze acquisition [...]
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
12/05/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection [...]
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
12/05/2026
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial 1 Participants treated with the [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
12/05/2026
ORION CORPORATION PRESS RELEASE 12 MAY 2026 at 10:30 EEST Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs Orion [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System
12/05/2026
New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands planned for later this summer Enables insulin automation to be controlled [...]
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
12/05/2026
Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical development AstronauTx also appoints Deb Gouveia as Vice [...]
Transactions in connection with share buy-back program
12/05/2026
Company announcement no. 16 - 26 12 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12/05/2026
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cells Correlation established between EO2463-induced and B cell target-specific CD8 T- [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
Rapid Nutrition Extends AI-Powered Agentic Platform to Consumer Ecosystem Following Investor Rollout
12/05/2026
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, today announced the [...]
Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed
12/05/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed Männedorf, [...]
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
12/05/2026
May 12, 2026 News release BioPorto A/S to h ost an investor webcast on the results for the first quarter of 202 6 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR [...]
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
12/05/2026
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single ‑ assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis [...]
Gala Health GLP-1 Compounded and Branded Weight Loss Medication Options with Real Doctor Support
12/05/2026
How Gala GLP-1 Compounded Semaglutide, Tirzepatide, and Microdosing Options Work for Prescription Weight Management Without Insurance in 2026 Wilmington, Delaware, May 11, 2026 (GLOBE NEWSWIRE) -- Compounded medications [...]
Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies
12/05/2026
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of concept First-of-its-kind collaboration between a specialist biotech venture firm and a [...]

Pages